Other GLP-1 receptor agonists, including liraglutide and semaglutide, are now being evaluated clinically across several substance use disorder domains (alcohol, nicotine, cocaine, and opioid use disorder), with multiple trials ongoing (NCT05895643, NCT07227948, NCT06924697 at ClinicalTrials.gov) or recently completed (Klausen et al., 2022
Flaconcino, acqua e dose sono noti Le tacche misurano il volume, non il principio attivo
How This Blind Spot Leads Directly Into the Next Crisis If we cannot explain how GLP-1 agonists exert their multi-system effects, then we cannot reliably determine who benefits from them, why certain responses emerge, or which biological signatures distinguish durable responders from partial responders, early plateauers, non-responders, or individuals at risk for muscle loss, inflammatory rebound, or neuroprotective divergence
Oncogene 30 , 32343247 (2011)
The Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) do not list iron deficiency or anaemia as recognised adverse effects of semaglutide